Merck Inc., known as MSD outside of the United States and Canada, announced positive data from multiple Phase II studies evaluating V 116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa